Last update: Dec. 4, 2020
Minimal risk for breastfeeding and infant.
Used in the treatment and prophylaxis of influenza A and B.
Administered via inhalation or intravenously in two daily doses.
The low plasma concentrations reached make it unlikely that significant amounts will transfer into breastmilk (Tanaka 2009).
Its very low oral absorption, 2% (Cass 1999), prevents transfer into infant plasma from breastmilk (Skalli 2010, Tanaka 2009).
Its use is authorized in infants from 6 months of age.
Various medical associations and expert consensus consider its use to be safe during breastfeeding (Skalli 2010, Chen 2010, Tanaka 2009, ABM 2009, AEM 2009).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2021 from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM